Signs and Symptoms, Digestive Clinical Trial
Official title:
Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms
A Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Probiatop in the Treatment of Digestive Symptoms. Phase IV. The casuistic presented in this protocol is 150 participants randomized at a 1:1 ratio (75 receiving Probiatop and 75 receiving placebo), balanced by age, sex, prebiotic intake* and summation of the Gastrointestinal Symptom Rating Scale (GSRS) questions related to the domains of diarrhea (questions 11, 12, and 14), indigestion (questions 6, 7, 8, and 9), and constipation (questions 10, 13, and 15) separated by intensity and frequency. Participants with recurrent digestive symptoms for at least 3 months, with a score of 21 on the sum of questions 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 of the GSRS (corresponding to the domains diarrhea, indigestion and constipation) will be randomized to Probiatop or placebo.
This is a Phase IV clinical trial that will evaluate the efficacy and safety of Probiatop (investigational product). Participants with recurrent digestive symptoms for at least 3 months, with a score of 21 on the sum of questions: 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 of the GSRS questionnaire (corresponding to the domains diarrhea, indigestion and constipation) will be randomized to Probiatop or placebo. It will also be applied by electronic means (whatsapp link) on D7, D21 and D35. On these days participants will also be contacted by telemedicine to collect adverse events adverse events and data on concomitant medication. Treatment will be discontinued on D42. On D70 the participant will again be contacted by telemedicine for final data collection. Product under investigation and dosage: Probiatop composition: association of probiotic strains containing 1 g/sachet of 1 x 109 CFU Bifidobacterium lactis HN019 (ATCC SD 5674), 1 x 109 CFU Lactobacillus acidophilus NCFM (ATCC SD 5221), 1 x 109 CFU Lactobacillus rhamnosus HN001 / Lacticaseibacillus rhamnosus HN001 (ATCC SD 5675) and 1 x 109 CFU Lactobacillus paracasei Lpc-37 / Lacticaseibacillus paracasei Lpc-37 (ATCC SD 5275). Placebo composition: collagen ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02530762 -
Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber
|
N/A | |
| Completed |
NCT02532985 -
Gastrointestinal Tolerability Following Multiple Servings of a Novel Dietary Fiber
|
N/A | |
| Recruiting |
NCT01464814 -
Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules
|
N/A | |
| Completed |
NCT02180035 -
Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS
|
N/A | |
| Recruiting |
NCT02928484 -
Evaluation of the Effect of a Probiotic Supplement Upon Gastrointestinal Function
|
Phase 1/Phase 2 | |
| Completed |
NCT02519374 -
Fiber Tolerability in Children
|
N/A | |
| Completed |
NCT02677090 -
Fiber Tolerability in Children Aged 3-7 Year
|
N/A | |
| Completed |
NCT00822328 -
Fermented Milk Drink on Human Intestinal Microflora
|
Phase 2 | |
| Completed |
NCT02253628 -
The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.
|
N/A | |
| Completed |
NCT00251992 -
Nexium Dyspepsia/AST
|
Phase 3 | |
| Completed |
NCT00251914 -
Nexium Dyspepsia/AST
|
Phase 3 | |
| Completed |
NCT01431482 -
Evaluation of the Composition of Human Milk and Health Outcomes in Children
|
||
| Terminated |
NCT01675960 -
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
|
Phase 2 | |
| Completed |
NCT00652834 -
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
|
Phase 4 | |
| Active, not recruiting |
NCT00110708 -
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
|
Phase 2 |